Clinical Trials Logo

Metabolic Syndrome clinical trials

View clinical trials related to Metabolic Syndrome.

Filter by:

NCT ID: NCT05839444 Completed - Metabolic Syndrome Clinical Trials

A Clinical Study to Evaluate the Safety and Tolerability of BioPB-01 in Healthy Adults

Start date: April 27, 2023
Phase: N/A
Study type: Interventional

The present study is a randomized, placebo-controlled, parallel-group, double-blind clinical study. Seventy-eight individuals will be screened, and considering a screening failure rate of 20%, approximately 64 participants will be randomized in a ratio of 1:1 to receive either BioPB-01 or Placebo

NCT ID: NCT05830552 Completed - Metabolic Syndrome Clinical Trials

The Effect of Feedback on Physical Activity Surveillance Using Wearable Device-Smartphone Application for Resolution of Metabolic Syndrome in Aged 60 or Older

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

The Effect of Feedback on Physical Activity Surveillance using Wearable Device-Smartphone Application for Resolution of Metabolic Syndrome in Aged 60 or older; a 12-Week Randomized Control Study

NCT ID: NCT05811923 Completed - Metabolic Syndrome Clinical Trials

Changes in Metabolic Rate and Perceptual Indicators After Acute Ingestion of Paraxanthine

PX
Start date: December 12, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the acute impact of ingesting individual and combined dosages of caffeine and paraxanthine in comparison to placebo on changes in resting metabolic rate, perceived levels of affect, and markers of lipolysis.

NCT ID: NCT05808192 Completed - Single Transplant Clinical Trials

De Novo Metabolic Syndrome in Liver Transplant Patients After Immunosuppression Withdrawal

Start date: September 1, 2020
Phase:
Study type: Observational

Evaluate de novo onset of metabolic syndrome, NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy ("tolerant") and in those taking immunosuppressive therapy ("non-tolerant").

NCT ID: NCT05805488 Completed - Metabolic Syndrome Clinical Trials

Evaluation of the Body Slimming Effect of TCI904

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

To assess the efficacy of Lactobacillus delbrueckii ssp. bulgaricus TCI904 on body slimming

NCT ID: NCT05713773 Completed - Obesity Clinical Trials

Pharmacodynamics and Pharmacokinetics of 3 New Developed Coated Glucose Beads in 20 Obese Healthy Subjects

Start date: October 25, 2019
Phase: Phase 1
Study type: Interventional

This single-dose, randomized, open label, five-treatment, five-period, five-sequence crossover study was performed to assess pharmacodynamics (PD) and pharmacokinetics (PK) of three new developed coated Glucose beads formulations (containing glucose (8 g) and caffeine), one coated Glucose beads formulation (containing glucose (8 g)) and one uncoated Glucose beads formulation (containing Glucose (8 g) and caffeine) after single-dose administration (fasting conditions) in 20 obese healthy subjects. After an overnight fasting of at least 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position. At least 3 days wash-out period was kept between each treatment periods.

NCT ID: NCT05703438 Completed - Clinical trials for Metabolic Syndrome, Protection Against

The Effect of a Low-calorie Diet With Balanced Nutrition on Metabolic Syndrome

Start date: August 5, 2022
Phase: N/A
Study type: Interventional

The study looked at how a nutritionally balanced low-calorie diet based on traditional Indonesian foods affected obese people's metabolic biomarkers. The traditional Indonesian foods presented here are Minangkabau cuisine. Body mass index, waist circumference, systolic and diastolic blood pressure, body fat mass percentage, fasting blood sugar levels, and lipid profiles are among the metabolic biomarkers measured. The provision of a balanced nutritionally low-calorie diet based on traditional Indonesian foods, according to the researchers, will have a significant effect on the metabolic biomarkers of obese people.

NCT ID: NCT05698381 Completed - Depression Clinical Trials

Daily Vinegar Ingestion and Metabolic Health

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if vinegar ingestion promotes beneficial changes to metabolic health parameters in healthy, overweight adults.

NCT ID: NCT05688917 Completed - Obesity Clinical Trials

Green Coffee Effect on Metabolic Syndrome

Start date: September 3, 2020
Phase: N/A
Study type: Interventional

The present study aimed to investigate the effect of green coffee bean extract (GCBE) on the inflammatory biomarkers in obese patients with a metabolic syndrome via analyzing some inflammatory biomarkers as resistin, TNF-α, total sialic acid, homocysteine, high sensitivity C-reactive protein (hs-CRP) and anti-inflammatory cytokine, adiponectin

NCT ID: NCT05685017 Completed - Obesity Clinical Trials

Adiponectin, ICAM-1, VCAM-1 Levels and Metabolic Syndrome in Obese Adolescents

ICAM; VCAM
Start date: October 1, 2019
Phase:
Study type: Observational [Patient Registry]

Adipose tissue secreting a number of adipokines which regulate insulin sensitivity, energy metabolism and vascular homeostasis, so the dysfunction of adipose tissue is linked with the incidence of obesity accompanied with insulin resistance, hypertension and cardiovascular disease (1). Obesity is known to alters the expression of adipokines due to the adipose tissue hypertrophy (2), including adiponectin, in which able to exert a potent anti-inflammatory and vascular protective effect (2). It has been proposed that adiponectin acts to prevent the vascular dysfunction due to obesity and diabetes by improves insulin sensitivity and metabolic profiles to reduce the risk factors for cardiovascular disease and protects the vasculature through its pleiotropic actions on endothelial cells, endothelial progenitor cells, smooth muscle cells and macrophages (1). The concentrations of adiponectin of 5 to 25 mg/mL had a significant inhibitory effect on the expression of monocyte adhesion and adhesion molecule induced by TNF-α in vitro. Atherosclerosis is an inflammatory disease in which adhesion molecules on arterial endothelial cells are responsible for the accumulation of monocytes/macrophages and T lymphocytes. While obesity is low-grade inflammation in which make a contribution on endothelial dysfunction by increasing the oxygen-derived free radicals (ROS) due to adipocyte hypertrophy, leads to an endoplasmic reticulum (ER) stress and mitochondrial dysfunction (3). Adiponectin is accumulated in the vasculature, and it reduced on obesity due to suppression by TNF-α and lead to adiponectin-deficiency which stimulate the significant increases of Vascular cell adhesion protein 1 (VCAM-1) and Intercellular Adhesion Molecule 1 (ICAM-1) or known as CD54 in aortic intima (4). Here we investigate the level of adiponectin, ICAM-1, VCAM-1 with the incidence of MetS in obese adolescents.